The Phase III global study of EG12014 in patients with early breast cancer.

Trial Profile

The Phase III global study of EG12014 in patients with early breast cancer.

Planning
Phase of Trial: Phase III

Latest Information Update: 15 May 2017

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 May 2017 New trial record
    • 02 May 2017 According to an EirGenix media release, the design of this Phase III study, along with the regulatory strategy of EG12014 biosimilar program, will be discussed in the regulatory meetings with the EMA and FDA in Q2-Q3, 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top